We develop and apply physiologically relevant human organoid systems for disease modeling, therapeutic testing, and mechanistic studies.
_ARR3_GFP%20(1).jpg)
Our protocols deliver markedly lower batch-to-batch variation than competitors, while reaching human-relevant developmental maturity far faster, for predictable, dependable data.
Shown here for our iPSC-derived retinal organoids as a representative example of the platform's reproducibility.
Our retinal organoid model illustrates the level of biological complexity and characterization achieved across our platform. It contains all major retinal cell types organized in their native layered architecture, confirmed by brightfield and immunofluorescence imaging. Every model system below is characterized with the same level of depth and rigor.


.jpg)

Brain organoids are iPSC-derived models in which multiple neural cell types self-organize into tissue-like structures, making it possible to study cellular interactions and region-specific biology in a human in vitro system.
We generate whole-brain (cerebral) and region-specific organoids:
Day 20 · BF
Day 50 · IF
Day 20 · BF
Day 50 · IF
Day 20 · BF
Day 75 · IFOur retinal organoids are used to model inherited retinal disease, test gene and cell therapies, and assess retinal safety of new compounds in a human system.



Our cardiac platforms range from 2D cardiomyocyte monolayers to 3D cardiac organoids, with spontaneous contraction, calcium signaling, and electrophysiology as direct functional readouts for disease modeling and cardiotoxicity testing.




A connected set of iPSC-derived models, from spinal cord, skeletal muscle, and neuromuscular organoids to functional spinal motor neurons, for studying motor-neuron and muscle biology, ALS, spinal muscular atrophy, and therapeutic response.

.jpg)






Lung organoids recapitulate human airway and alveolar epithelium, including cell-type diversity and epithelial organization.
Our 100%S condition produces organoids with the apical side facing outward, closer to in vivo conditions for bacterial infection studies and antibiotic testing.


Tumor organoids, including high-grade glioma and glioblastoma (GBM), are generated from patient tumor material and preserve the heterogeneity, invasive behavior, and molecular signatures of the original tumor.
We use them for therapy response testing, biomarker discovery, and mechanistic studies, with matched snRNA-seq, proteomics, and epigenomic profiling through our multi-omics services.
Day 26 · BF